Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954363 | 1.00 | CYP3A4 (0.46) | CYP3A4ALDH1A1APOBEC3GRAPGEF4CD44 | |
| SCHEMBL12887727 | 0.82 | CD44 (0.34) | CYP3A4CD44PKMSMN1; SMN2CYP2D6 | |
| SCHEMBL2916024 | 0.78 | AHR (0.43) | CYP3A4ALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL6065091 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29353234 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12246987 | 0.74 | — | — | |
| SCHEMBL9607652 | 0.73 | HSD17B10 (0.50) | CYP3A4ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL12446580 | 0.73 | MEN1 (0.38) | CYP3A4ALDH1A1RAPGEF4MAPTGAA | |
| SCHEMBL12619112 | 0.73 | MAPT (0.35) | ALDH1A1MAPTGAANPC1SMN1; SMN2 | |
| SCHEMBL10106234 | 0.73 | TSHR (0.50) | CYP3A4ALDH1A1CD44MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016457-A1 | NEW SUBSTITUTED HETEROCYCLIC COMPOUND AS GSPTS/MYC SIGNAL FLUX REGULATOR | 杭州德睿智药科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9643952-B2 | Pyridone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| US-20150315172-A1 | PYRIDONE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-7951827-B2 | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | CYP3A4 1253/4885ALDH1A1 502/4885APOBEC3G 3407/4885 |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | CYP3A4 478/4885ALDH1A1 1338/4885APOBEC3G 4077/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | CYP3A4 144/4885ALDH1A1 565/4885APOBEC3G 3338/4885 |
| US-20150315172-A1 | PYRIDONE COMPOUND | HRH4, HRH3, HRH1 | CYP3A4 422/4885ALDH1A1 443/4885APOBEC3G 3895/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | CYP3A4 910/4885ALDH1A1 265/4885APOBEC3G 4691/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | CYP3A4 478/4885ALDH1A1 1338/4885APOBEC3G 4077/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | CYP3A4 3162/4885ALDH1A1 4066/4885APOBEC3G 4564/4885 |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | KCNJ2, KCNJ1, KCNJ11 | CYP3A4 914/4885ALDH1A1 4563/4885APOBEC3G 2575/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | CYP3A4 236/4885ALDH1A1 475/4885APOBEC3G 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.